Özet:

Introduction: It is closely associated with hypogonadism, metabolic syndrome and non-alcoholic fatty liver disease (NAFLD). In our study, we aimed to examine the relationship between testosterone treatment applied to hypogonad patients and non-alcoholic fatty liver disease using Fibroscan and laboratory data. Material-method: Forty hypogonads and 36 eugonads aged 8-60 years without treatment were included in the study. BMI, waist circumference and laboratory measurements (glucose, liver function tests, hormone and lipid panel) of all participants were measured. In addition, hepatosteatosis level was evaluated with Fibroscan® (transient elastography) procedure. Results: In our study, the mean (CAP score) hepatosteatosis level of the hypogonad group was higher than the control group (274. 72±78.69 dB/m and 207. 41±52.82 dB/m, p=0.000, respectively). After testosterone treatment, a decrease was observed in the mean waist circumference, hepatosteatosis level and laboratory values (AST, ALT, Fasting plasma glucose, Total-C, LDL, TG, insulin) of the hypogonad group. However, of these, AST, ALT, LDL-C, TG, total testosterone level, waist circumference and additionally body mass index were directly correlated with the mean hepatosteatosis level. When logistic regression analysis was performed, the most significant parameter predicting hepatosteatosis was found to be total testosterone level (OR: 0.004, 95% CI: 0.988-0.998). Conclusion: The incidence of NAFLD is increased in male patients with hypogonadism compared to eugonad males. Total testosterone level, BMI, Waist Circumference are independent risk factors for the development of NAFLD. Therefore, we think that testosterone replacement therapy can improve NAFLD and accompanying metabolic syndrome parameters.

Anahtar Kelimeler: